The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Are adverse events (AEs) during first-line FOLFIRINOX (FFX) more frequent in real-world (RW) patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who do not proceed to second-line therapy?
 
Ravi Kumar Paluri
Honoraria - Exelixis; Ipsen; Seagen
Consulting or Advisory Role - Exelixis; Ipsen
Speakers' Bureau - Exelixis; Ipsen
Research Funding - Geistlich Pharma; Minneamrita Therapeutics; Seagen
 
Michelle Silver
Research Funding - Ipsen (Inst)
 
Paul Cockrum
Employment - Ipsen
Stock and Other Ownership Interests - Ipsen
Research Funding - Ipsen (Inst)
 
Syvart Dennen
Research Funding - Ipsen (Inst)